education
Download App
Indonesia
search
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Country
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
search
UserName
Profession
Email
Account
Manage Account
Change Password
Sign Out
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Other Services
Education
Download App
Country
Indonesia
Hong Kong
India
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Australia
Korea
New Zealand
Account
Masuk
Home
Find Drugs
Pill Identifier
Find Drug Company
Diseases
Medical News & Updates
Advertisement
Advertisement
MIMS home
Drugs
Info
Xybat
Xybat
levocetirizine
Manufacturer:
Interbat
Marketer:
Interbat
SELECT
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Bahasa Concise Prescribing Info
Concise Prescribing Info
Contents
Levocetirizine diHCl
Indications/Uses
Allergic rhinitis. Chronic idiopathic urticaria.
Dosage/Direction for Use
FC tab
Adult & childn ≥12 yr
5 mg once daily.
Syr
Childn ≥12 yr
5 mg once daily,
6-11 yr
2.5 mg once daily,
6 mth-5 yr
1.25 mg once daily.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. ESRD at <10 mL/min CrCl or patients undergoing hemodialysis.
Special Precautions
Avoid concurrent use of alcohol or other CNS depressants. Patients w/ predisposing factors of urinary retention.
Adverse Reactions
Headache, somnolence, seizure, paresthesia, vertigo, loss of consciousness, tremor, dysgeusia, dry mouth, nausea, vomiting, diarrhea, edema, anaphylaxis, agitated, urticaria, abnormal liver function.
View
ADR Reporting Link
MIMS Class
Antihistamines & Antiallergics
ATC Classification
R06AE09 - levocetirizine ; Belongs to the class of piperazine derivatives used as systemic antihistamines.
Regulatory Classification
K
Presentation/Packing
Form
Xybat FC tab 5 mg
Packing/Price
3 × 10's
Form
Xybat syr 2.5 mg/5 mL
Packing/Price
60 mL x 1's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Daftar Gratis untuk melanjutkan membaca
Lanjutkan dengan Google
Daftar dengan email
Sudah punya akun?
Masuk